Ginkgo Datapoints, Apheris Announce Founding Members of Antibody Developability Consortium
The consortium aims to address antibody development bottlenecks by creating standardized datasets and AI models that support earlier risk detection and more informed candidate selection. The post Ginkgo Datapoints, Apheris Announce Founding Members of Antibody Developability Consortium appeared first on GEN - Genetic Engineering and Biotechnology News .
Ginkgo Datapoints and Apheris have introduced the founding members of the Antibody Developability Consortium, an industry collaboration to help predict manufacturability and developability risks in antibody candidates. The consortium's goal is to create a comprehensive dataset for machine learning, addressing current limitations in convenience datasets.
AbbVie, Agenix, Lundbeck, and Takeda are among the founding members, with the possibility of additional pharma and biotech companies joining. Gingko Datapoints, an offering of Gingko Bioworks, will contribute proprietary antibody sequencing, filling any gaps from publicly available sources, aiming to reach 10,000 antibodies in total.
The consortium's scientific design and execution will be led by Gingko Datapoints, including sequence selection, antibody production, and high-throughput wet-lab characterization. Apheris' federated infrastructure will deliver the foundation model into each member's environment for fine-tuning on proprietary data. Independent scientific oversight will be provided by Charlotte Deane, PhD, and Peter Tessier, PhD.
Members will have access to the initial dataset by early 2027, with plans to include more complex antibody formats in the future to predict the success or failure of various drug classes.
Written by urgent.news from GEN Biotechnology's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
